Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20491528 | 1.00 | LMNA (0.37) | LMNACTSLCTSBCTSKKDM4E | |
| SCHEMBL2208804 | 1.00 | LMNA (0.37) | LMNACTSLCTSBCTSKKDM4E | |
| SCHEMBL2206227 | 1.00 | LMNA (0.37) | LMNACTSLCTSBCTSKKDM4E | |
| SCHEMBL1710717 | 0.98 | LMNA (0.39) | LMNACTSLCTSBCTSKKDM4E | |
| SCHEMBL121125 | 0.93 | LMNA (0.39) | LMNACTSLCTSBCTSKKDM4E | |
| SCHEMBL14414058 | 0.88 | USP2 (0.42) | LMNAKDM4EUSP2ALDH1A1MMP9 | |
| SCHEMBL1062380 | 0.88 | — | — | |
| SCHEMBL7705221 | 0.88 | USP2 (0.42) | LMNAKDM4EUSP2ALDH1A1MMP9 | |
| Propionaldehyde SCHEMBL8776133 | 0.86 | ALDH1A1 (0.33) | LMNAKDM4EUSP2ALDH1A1MMP9 | |
| SCHEMBL5717940 | 0.83 | CTSL (0.35) | LMNACTSLCTSBCTSKCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472810-B2 | Imidazopyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2022-10-18 | — | — | US | disclosed |
| US-20210238182-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2021-08-05 | — | — | US | disclosed |
| US-10912773-B2 | Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2021-02-09 | — | — | US | disclosed |
| US-10905688-B2 | Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2021-02-02 | — | — | US | disclosed |
| US-10858362-B2 | Imidazopyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2020-12-08 | — | — | US | disclosed |
| EP-3532064-B1 | COMBINATION TREATMENTS COMPRISING IMIDAZOPYRAZINONES FOR THE TREATMENT OF PSYCHIATRIC AND/OR COGNITIVE DISORDERS | H LUNDBECK AS (DK) | 2020-07-29 | — | — | EP | disclosed |
| US-20190282572-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | H. LUNDBECKA/S (DK) | 2019-09-19 | — | — | US | disclosed |
| US-20190282571-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | H. LUNDBECK A/S (DK) | 2019-09-19 | — | — | US | disclosed |
| EP-3532064-A1 | COMBINATION TREATMENTS COMPRISING IMIDAZOPYRAZINONES FOR THE TREATMENT OF PSYCHIATRIC AND/OR COGNITIVE DISORDERS | H. Lundbeck A/S (DK) | 2019-09-04 | — | — | EP | disclosed |
| EP-3532053-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | H. Lundbeck A/S (DK) | 2019-09-04 | — | — | EP | disclosed |
| EP-0990653-A1 | 2-OXOIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2000-04-05 | — | — | EP | disclosed |
| US-6040449-A | USEFUL FOR FORMING FLUORINE CONTAINING 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES, USEFUL AS ANTAGONIST FOR MUSCARINIC M3 RECEPTORS AND LESS SIDE EFFECT | BANYU PHARMACEUTICAL CO LTD (JP) | 2000-03-21 | — | — | US | disclosed |
| US-6030972-A | 2- OR 5-AMINOMETHYL,2- OR 5-CYANOPYRIMIDINES AS INTERMEDIATES OF ANTICOAGULANTS IN EXTRACORPOREAL CIRCULATION (HEART-LUNG MACHINE, HEMODIALYSIS) | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-29 | — | — | US | disclosed |
| US-5968923-A | ANTIINFLAMMATORY AGENTS, TREATMENT OF NERVOUS SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS | PFIZER INC. (US) | 1999-10-19 | — | — | US | disclosed |
| US-5948792-A | POTENT AND SELECTIVE ANTAGONISTS FOR MUSCARINIC M.SUB.3 RECEPTORS WITH LITTLE SIDE EFFECTS. | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0930298-A1 | FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
| US-5750540-A | SIDE EFFECT REDUCTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| EP-0823423-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-02-11 | — | — | EP | disclosed |
| EP-0775132-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | Pfizer Limited (GB) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996005193-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282571-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | PDE12, PDE1B, PDE1A | LMNA 3593/4885CTSL 954/4885CTSB 356/4885 |
| US-10858362-B2 | Imidazopyrazinones as PDE1 inhibitors | PDE12, PDE4A, PDE5A | LMNA 3856/4885CTSL 3227/4885CTSB 2356/4885 |
| US-20210238182-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | PDE12, PDE4A, PDE5A | LMNA 3856/4885CTSL 3227/4885CTSB 2356/4885 |
| US-11472810-B2 | Imidazopyrazinones as PDE1 inhibitors | PDE12, PDE4A, PDE5A | LMNA 3856/4885CTSL 3227/4885CTSB 2356/4885 |
| US-10912773-B2 | Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors | PDE5A, PDE3A, PDE12 | LMNA 3933/4885CTSL 3345/4885CTSB 1719/4885 |
| US-10905688-B2 | Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors | PDE1A, PDE12, PDE1B | LMNA 3716/4885CTSL 897/4885CTSB 348/4885 |
| US-20190282572-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | PDE12, PDE4A, PDE1A | LMNA 4126/4885CTSL 2631/4885CTSB 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.